Sites should avoid relying on sponsors when implementing quality policies, expert warns. “Each sponsor will tell you something different” and the result can be a complex mess.
“DCTs are here to stay. PI oversight is even more important now.”
A highly anticipated trial in sub-Saharan Africa is the first to specifically evaluate the efficacy of a COVID-19 vaccine in people living with HIV.
“Retention is a chronic challenge” in clinical trials. A key to overcoming it is physician engagement, expert says.
Early approval pathways for drugs often result in access accompanied by a persistent lack of evidence of benefit, experts say.